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Introduction {#cjp244-sec-0001}
============

Significant advances in understanding the molecular pathways involved in the pathogenesis of colorectal cancer (CRC) have been achieved in the past three decades. The recognition of a 'serrated' pathway to CRC has challenged the previously held notion that CRCs developed exclusively from conventional adenomas [1](#cjp244-bib-0001){ref-type="ref"}. Serrated polyps, named because of their characteristic 'saw‐toothed' histological appearance, are thought to progress to CRC via a sequence of molecular events which frequently include activation of the mitogen‐activated protein kinase (MAPK) pathway through mutations of *BRAF* or *KRAS* oncogenes, as well as epigenetic silencing of genes through promoter hypermethylation (termed CpG island methylator phenotype, CIMP) [2](#cjp244-bib-0002){ref-type="ref"}, [3](#cjp244-bib-0003){ref-type="ref"}, [4](#cjp244-bib-0004){ref-type="ref"}, [5](#cjp244-bib-0005){ref-type="ref"}.

Serrated polyposis, previously known as hyperplastic polyposis syndrome, is a rare condition characterised by the presence of numerous serrated polyps in the large intestine. The current definition of serrated polyposis is shown in Table [1](#cjp244-tbl-0001){ref-type="table-wrap"} [6](#cjp244-bib-0006){ref-type="ref"}. The syndrome is associated with an increased risk of CRC [7](#cjp244-bib-0007){ref-type="ref"}, [8](#cjp244-bib-0008){ref-type="ref"}, [9](#cjp244-bib-0009){ref-type="ref"}, [10](#cjp244-bib-0010){ref-type="ref"}, [11](#cjp244-bib-0011){ref-type="ref"} and has many hallmarks of a disease caused by a pathogenic germline genetic mutation. These include restricted ethnicity to individuals with Northern European ancestry [10](#cjp244-bib-0010){ref-type="ref"}, [11](#cjp244-bib-0011){ref-type="ref"}, familial clustering, and increased risk of CRC in the relatives of serrated polyposis individuals [12](#cjp244-bib-0012){ref-type="ref"}, [13](#cjp244-bib-0013){ref-type="ref"}. To date however, the molecular basis of serrated polyposis remains unknown.

###### 

World Health Organization clinical criteria for the identification of serrated polyposis [16](#cjp244-bib-0016){ref-type="ref"}

  ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  **Criterion 1**   At least five serrated polyps located proximal to the sigmoid colon, two of which are larger than 10 mm in diameter
  **Criterion 2**   Any number of serrated polyps located proximal to the sigmoid colon in an individual who has a first degree relative with serrated polyposis
  **Criterion 3**   More than 20 serrated polyps of any size distributed throughout the colon
  ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------

For this reason, serrated polyposis is currently defined by an arbitrary set of clinical parameters which describe a heterogeneous group of patients. Studies evaluating the molecular characteristics of colonic lesions in individuals with serrated polyposis have been limited by relatively small sample size, and by heterogeneity in the patients recruited. The aim of this systematic review and meta‐analysis is to summarise the literature on the molecular features of CRCs and their precursor lesions in patients with serrated polyposis, in order to identify patterns which could be used as the basis for future research into this condition.

Methods {#cjp244-sec-0002}
=======

Our meta‐analysis adhered to the PRISMA statements for reporting on systematic reviews and the STREGA recommendations for reporting of genetic association studies [14](#cjp244-bib-0014){ref-type="ref"}, [15](#cjp244-bib-0015){ref-type="ref"}. Given that the diagnostic criteria and nomenclature for serrated polyps were only formalised in 2010 [6](#cjp244-bib-0006){ref-type="ref"} and that most sessile serrated adenomas polyps (SSA/Ps) were previously identified as hyperplastic polyps (HPs), the term serrated polyp was used to describe all polyps with a serrated histological architecture, including HPs, SSA/Ps, traditional serrated adenomas and mixed serrated polyps (MP). Lesions proximal to the splenic flexure, including those from the caecum, ascending and transverse colon, were classified as proximal; lesions from the splenic flexure, descending colon, sigmoid colon and rectum were classified as distal.

Search strategy {#cjp244-sec-0003}
---------------

Three investigators (LW, MS, EH) independently searched Medline and EMBASE for articles published before Jan 1st 2015 relating to serrated polyposis. The search was conducted using the following key words as both MeSH terms and text words: ('hyperplastic polyposis' OR 'intestinal polyposis' OR 'serrated polyposis') AND ('colon OR colonic OR colorectal') AND ('polyp OR neoplasm OR neoplasia OR carcinoma OR cancer'). In addition, reference lists of identified articles were searched for additional relevant references.

Study selection criteria {#cjp244-sec-0004}
------------------------

Each manuscript was reviewed for inclusion according to the following criteria: (1) full article was published in peer reviewed journals, (2) the study participants fulfilled the WHO criteria for serrated polyposis [16](#cjp244-bib-0016){ref-type="ref"} (see Table [1](#cjp244-tbl-0001){ref-type="table-wrap"}) and (3) the study reported the histological and molecular characteristics of colonic polyps and/or cancers collected from individuals with serrated polyposis. Studies which did not describe study participants according to the WHO criteria were included if the investigators were able to use primary data to retrospectively apply the WHO criteria. Investigators LW, MS and EH independently conducted the search, reviewed the manuscripts, and extracted data from the included studies, with disagreements and queries resolved through re‐evaluation of study and discussion.

Data extraction {#cjp244-sec-0005}
---------------

Using a structured template, the following data were extracted by each investigator: first author\'s name, year of publication, recruitment and ascertainment method of individuals, histological and molecular characteristics of colonic neoplasms studied. Molecular characteristics were chosen to reflect key steps in the serrated pathway, including (1) mutation of the *BRAF* or *KRAS* oncogenes, (2) CIMP, categorised as CIMP‐high, CIMP‐low or CIMP‐negative, (3) immunohistochemical (IHC) expression of mismatch repair proteins MLH1, MSH2, MSH6 and PMS2, and (4) microsatellite instability (MSI) status categorised as MSI‐high (MSI‐H), MSI‐low (MSI‐L) or MS stable (MSS).

Statistical analysis {#cjp244-sec-0006}
--------------------

We calculated the prevalence of key molecular characteristics by dividing the total number of colonic neoplasms with the molecular alteration of interest by the total number of neoplasms in each histological category (serrated polyp, conventional adenoma and CRC). Serrated polyps contiguous with CRC were excluded from the meta‐analysis as they were likely to have molecular features found in both serrated polyps and CRCs, making interpretation of results difficult [17](#cjp244-bib-0017){ref-type="ref"}.

As the majority of studies did not report on the proportion of polyps sampled for molecular analysis from each patient, we therefore calculated the mean number of polyps per patient as a means of assessing heterogeneity in the study populations, and hence the validity of pooling data from the studies. Meta‐analysis was performed if mean polyp counts per patient were comparable across studies. Since the proportion of lesions carrying the molecular abnormality of interest was 0 or 1 in some of the included studies, we enabled the Freeman‐Tukey double arcsine transformation so that these studies would be included in the analysis. We used random effects meta‐analysis to calculate the pooled estimates of the proportion with 95% confidence interval (CI) [18](#cjp244-bib-0018){ref-type="ref"}. Heterogeneity in the included studies was assessed using the I^2^ statistic, where I^2^ \> 50% indicates high heterogeneity, implying that the pooled results should be interpreted with caution. All data analyses were performed with STATA version 13.0 (StataCorp, TX, USA).

Results {#cjp244-sec-0007}
=======

We reviewed a total of 4561 reports, 40 of which were potentially eligible studies according to the title/abstract (Figure [1](#cjp244-fig-0001){ref-type="fig"}). After full review, 20 studies met the inclusion criteria. A further 6 studies were excluded from the meta‐analysis because data pertaining to patients with serrated polyposis were not extractable from the studies or the results of studies were not relevant to the meta‐analysis. There was no inter‐observer disagreement in the final list of included studies. The study designs, patient characteristics and colonic lesions analysed in each study are summarised in supplementary material, Table S1. The characteristics of studies excluded from the meta‐analysis and the reasons for their exclusion are summarised in supplementary material, Table S2. With the exception of one study, the median ages of study cohorts were in the range 50--66 years [19](#cjp244-bib-0019){ref-type="ref"}. There was substantial variability in the rate of CRC in the included primary study groups, which was lowest in individuals recruited from polyposis databases and highest in surgical series. As our calculations showed that the mean number of polyps per patient was comparable across the studies, we were able to proceed with the meta‐analysis.

![Flow chart showing the results of the search strategy and reasons for exclusion.](CJP2-2-127-g001){#cjp244-fig-0001}

Summary estimates {#cjp244-sec-0008}
-----------------

The proportion of serrated polyps, conventional adenomas and CRCs which harboured key molecular characteristics of interest, as analysed using random effects model, are shown in Table [2](#cjp244-tbl-0002){ref-type="table-wrap"}, and described further below.

###### 

Summary estimates of the prevalence (95% CIs) and testing for heterogeneity (I^2^) for molecular characteristics analysed in serrated polyposis, using a random effects model

  Molecular characteristics analysed               No. of studies   Summary estimate of prevalence % (95% CI)   Heterogeneity I^2^ statistic, *p* value
  ------------------------------------------------ ---------------- ------------------------------------------- -----------------------------------------
  ***BRAF*** mutation in serrated polyps           8                73 (65--80)                                 75%; *p* = 0.00
  ***BRAF*** mutation in conventional adenomas     6                0 (0--3)                                    27%; *p* = 0.23
  ***BRAF*** mutation in CRCs                      4                49 (33--64)                                 0%; *p* = 0.58
  ***KRAS*** mutation in serrated polyps           9                8 (5--11)                                   67%; *p* = 0.00
  ***KRAS*** mutation in conventional adenomas     7                3 (0--13)                                   45%; *p* = 0.09
  ***KRAS*** mutation in CRCs                      7                3 (0--16)                                   28%, *p* = 0.23
  Loss of **MLH1** expression in serrated polyps   6                3 (0--10)                                   85%, *p* = 0.0
  Loss of **MLH1** expression in CRCs              8                53 (36--71)                                 57%, *p* = 0.02
  **MSI** in CRC                                   5                40 (18--64)                                 45%, *p* = 0.12

Mutations of *BRAF* and *KRAS* oncogenes {#cjp244-sec-0009}
----------------------------------------

In the setting of serrated polyposis, the overall estimated rate of *BRAF* mutation was 73% (95% CI 65--80%) in serrated polyps, 0% (95% CI 0--3%) in conventional adenomas and 49% (95% CI 33--64%) in CRCs (Figure [2](#cjp244-fig-0002){ref-type="fig"}A--C). The rate of *BRAF* mutation was comparable in serrated polyps from the proximal colon (70%, 95% CI 54--85%) with those from the distal colon (68%, 95% CI 59--76%). Nearly all of the *BRAF*‐mutant cancers (94%, 95% CI 83--100%) were found in the proximal colon.

![*BRAF* mutations in the setting of Serrated Polyposis. Three panels showing summary estimates for the proportion of different lesional types carrying *BRAF* mutations in the setting of Serrated Polyposis. Panel A -- serrated polyps; Panel B -- conventional adenomas; Panel C -- colorectal cancers arising in the setting of Serrated Polyposis. ES = estimated proportion.](CJP2-2-127-g002){#cjp244-fig-0002}

The overall estimated rate of *KRAS* mutation was 8% (95% CI 5--11%) in serrated polyps, 3% (95% CI 0--13%) in conventional adenomas and 3% (95% CI 0--16%) in CRCs from patients with serrated polyposis (Figure [3](#cjp244-fig-0003){ref-type="fig"}A--C). *KRAS* mutation occurred in approximately 4% (95% CI 1--10%) of proximal serrated polyps and 11% (95% CI 3--20%) of distal serrated polyps.

![*KRAS* mutations in the setting of Serrated Polyposis. Three panels showing summary estimate for the proportion different lesional types carrying *KRAS* mutations in the setting of Serrated Polyposis. Panel A -- serrated polyps; Panel B -- conventional adenomas; Panel C -- colorectal cancers arising in the setting of Serrated Polyposis. ES = estimated proportion.](CJP2-2-127-g003){#cjp244-fig-0003}

In the studies which followed the formal diagnostic nomenclature for serrated polyps, the results of their molecular analyses could be stratified according to the histological subtype of serrated polyps [19](#cjp244-bib-0019){ref-type="ref"}, [20](#cjp244-bib-0020){ref-type="ref"}, [21](#cjp244-bib-0021){ref-type="ref"}, [22](#cjp244-bib-0022){ref-type="ref"}, [23](#cjp244-bib-0023){ref-type="ref"}. All of these studies sampled SSA/Ps and HPs for their molecular analyses, and the overall ratio of SSA/Ps to HPs sampled was approximately 1:1. *BRAF* mutation was found in 78% (95% CI 66--87%) of SSA/Ps and 54% (95% CI 33--73%) of HPs, whereas *KRAS* mutation was found in 2% of SSA/Ps (95% CI 0--6%) and 10% of HPs (95% CI 3--21%).

CpG island methylator phenotype {#cjp244-sec-0010}
-------------------------------

Although several studies reported on the CIMP status of serrated polyps and CRCs in the setting of serrated polyposis [21](#cjp244-bib-0021){ref-type="ref"}, [22](#cjp244-bib-0022){ref-type="ref"}, [24](#cjp244-bib-0024){ref-type="ref"}, [25](#cjp244-bib-0025){ref-type="ref"}, a meta‐analysis could not be conducted as studies varied in their definition of CIMP with the use of different gene panels and marker thresholds. Wynter *et al* used MINT loci (1, 2, 3, 12) to determine the CIMP status of serrated polyps. Of a total of 58 polyps, 35 (60%) were CIMP‐high, 16 (28%) were CIMP‐low, and 7 (12%) were CIMP‐negative [25](#cjp244-bib-0025){ref-type="ref"}. On the other hand, Guarinos *et al* used a commercial CIMP kit to investigate aberrant CpG island methylation in the promoters of *CACNA1G, CDKN2A, CRABP1, IGF‐2, MLH1, NEUROG1, RUNX3,* and *SOCS1*. It was reported that CIMP‐high status was found in 71.1% of SSA/Ps, 37.2% of microvesicular HPs and 17.6% of adenomas [22](#cjp244-bib-0022){ref-type="ref"}.

IHC analysis of mismatch repair genes and MSI {#cjp244-sec-0011}
---------------------------------------------

In the setting of serrated polyposis, absent IHC staining of MLH1 protein was estimated to occur in 3% (95% CI 0--10%) of serrated polyps and 53% (95% CI 36--71%) of CRCs (Figure [4](#cjp244-fig-0004){ref-type="fig"}A‐B). There was a paucity of data to permit meta‐analyses of the prevalence of MSH2, MSH6 and PMS2 protein expression. In the only study to have investigated IHC expression of MSH2 and MSH6 in this setting, it was reported that all of the serrated polyps showed normal expression of these proteins [26](#cjp244-bib-0026){ref-type="ref"}. Analysis of PMS2 expression was also restricted to a single study, where it was reported that loss of either MLH1 or PMS2 occurred in 2.9% (4 of 138) SSA/Ps [23](#cjp244-bib-0023){ref-type="ref"}. None of the studies investigated expression of MSH2, MSH6 and PMS2 protein expression in CRCs from patients with serrated polyposis.

![MLH1 loss in the setting of Serrated Polyposis. Panel A shows a summary estimate for the proportion of serrated polyps with MLH1 loss in the setting of Serrated Polyposis. Panel B shows the same data in relation to colorectal cancers arising in the setting of Serrated Polyposis. ES = estimated proportion; I^2^ = I squared heterogeneity statistic.](CJP2-2-127-g004){#cjp244-fig-0004}

MSI‐H was found in approximately 40% (95% CI 18--64%) of all CRCs in serrated polyposis (Figure [5](#cjp244-fig-0005){ref-type="fig"}). There were insufficient data to analyse for any overall association between loss of MLH1, MSI‐H and degree of dysplasia. However, a single study found that loss of MLH1 was significantly associated with MSI‐H lesions showing dysplasia or carcinoma compared with those which were MSI‐L or MSS [27](#cjp244-bib-0027){ref-type="ref"}.

![Summary estimate for the proportion of colorectal cancers that are MSI in the setting of Serrated Polyposis. ES = estimated proportion; I^2^ = I squared heterogeneity statistic.](CJP2-2-127-g005){#cjp244-fig-0005}

Sensitivity analysis {#cjp244-sec-0012}
--------------------

We performed sensitivity analysis to assess the impact on our estimates of excluding pre‐2010 studies in which the current definition of serrated polyposis was not used. For the estimates of *BRAF* and *KRAS* mutations in serrated polyps, conventional adenomas and CRCs, the results did not change substantially when these studies were excluded. Similarly, the estimated rate of MSI in CRCs did not change significantly with exclusion of pre‐2010 studies. The sensitivity analysis was remarkably robust compared to all of the main study findings. The only qualitative change was a lower rate in the loss of MLH1 expression in CRC, with a prevalence of 44% (95% CI 23--66%) compared to a value of 53% (95% CI 36--71%) in the main analysis.

Discussion {#cjp244-sec-0013}
==========

This is the first meta‐analysis focusing on the molecular characteristics of CRCs and their precursor lesions from individuals with serrated polyposis. Individuals with serrated polyposis have a significantly increased risk of developing CRC [7](#cjp244-bib-0007){ref-type="ref"}. Earlier studies have shown that serrated polyps in such individuals have higher rates of *BRAF* mutation compared with their sporadic counterparts [26](#cjp244-bib-0026){ref-type="ref"}, [28](#cjp244-bib-0028){ref-type="ref"}, [29](#cjp244-bib-0029){ref-type="ref"}, [30](#cjp244-bib-0030){ref-type="ref"}, [31](#cjp244-bib-0031){ref-type="ref"}. In our meta‐analysis, we have shown that CRCs from these individuals have higher rates of *BRAF* mutation compared to the general population; 49% (95% CI 35--60%) compared to 10--15% [32](#cjp244-bib-0032){ref-type="ref"}, [33](#cjp244-bib-0033){ref-type="ref"}. This is likely to be accounted for by the multitude of SSA/Ps found in serrated polyposis and is consistent with the hypothesis that CRCs in this setting develop from precursor SSA/Ps through the 'serrated' pathway [1](#cjp244-bib-0001){ref-type="ref"}.

As mutations in *BRAF* or *KRAS* oncogenes are frequently found as mutually exclusive events in serrated carcinomas, we added the rates of *BRAF* (49%) and *KRAS* (3%) mutations in CRCs from individuals with serrated polyposis to show that nearly half of all CRCs arising in this setting do not harbour mutations in either *BRAF* or *KRAS*. This suggests that mechanisms other than oncogenic mutations of *BRAF* or *KRAS* may be involved in the pathogenesis of serrated polyposis. Recent studies suggest that gene mutation status alone is not enough to define the complexity of the underlying biology of CRCs [34](#cjp244-bib-0034){ref-type="ref"}. Tian *et al* developed gene‐specific expression patterns to characterise an activating oncogenic signature for *KRAS*, *BRAF* and phosphatidyl inositol 3‐kinase (*PIK3CA*) in stage II/III CRCs [35](#cjp244-bib-0035){ref-type="ref"}. They found that 79 of the 206 tumours with no oncogenic mutations in *BRAF*, *KRAS* and *PI3KCA* could be classified as oncogenic based on their gene expression signatures. Multiple mechanisms were proposed for the oncogenic phenotype in wild‐type patients, including overexpression of key molecules within the MAPK pathway, overexpression of activators of the pathway as well as downregulation of inhibitors of the pathway [35](#cjp244-bib-0035){ref-type="ref"}.

Conventional adenomas are found in up to 90% of individuals with serrated polyposis and their presence is associated with an increased risk of colorectal cancer in these individuals [7](#cjp244-bib-0007){ref-type="ref"}, [8](#cjp244-bib-0008){ref-type="ref"}, [13](#cjp244-bib-0013){ref-type="ref"}, [23](#cjp244-bib-0023){ref-type="ref"}. However, only a few studies have investigated the molecular characteristics of conventional adenomas from individuals with serrated polyposis. Recently, Pai *et al* described a new polyp entity, atypical conventional adenoma, found in individuals who also have at least one SSA/P [36](#cjp244-bib-0036){ref-type="ref"}. Although these polyps were all wild‐type for *BRAF* or *KRAS* mutation, they share some morphological characteristics with serrated polyps including eosinophilic cytoplasm, focal serration and crypt dilatation. These atypical polyps demonstrated low levels of methylation. It is possible that a proportion of CRCs arising in individuals with serrated polyposis develop from conventional adenomas through a process mediated by DNA hypermethylation [32](#cjp244-bib-0032){ref-type="ref"}. Furthermore, although it has been proposed that DNA hypermethylation is mediated by activating mutation of the *BRAF* oncoprotein [5](#cjp244-bib-0005){ref-type="ref"}, it is also possible that activation of the *BRAF* oncoprotein may be mediated by DNA hypermethylation. However, while others have reported higher levels of CpG island methylation in both normal and lesional tissues from individuals with serrated polyposis [25](#cjp244-bib-0025){ref-type="ref"}, [37](#cjp244-bib-0037){ref-type="ref"}, this systematic review lacked sufficient data to allow meta‐analysis of the CIMP status of tumours. In addition, although epigenetic silencing of *MLH1* was shown to occur in approximately half of all CRCs in serrated polyposis, the role of other mismatch repair genes, DNA repair genes or tumour suppressor genes in colorectal carcinogenesis in serrated polyposis is yet unknown due to the limited number of studies which have investigated this.

Our analysis has several limitations, the most important of which is the heterogeneity across studies which have reported on the molecular characteristics of serrated polyposis. There may be multiple reasons for this. The studies were not population based, but drawn from a variety of different patient sources, including colorectal cancer databases, hospital records, polyposis databases, family cancer clinics and genetic clinics. This raises the possibility of ascertainment bias, particularly in those cohorts drawn from individuals presenting with symptomatic bowel cancer. The studies included in this meta‐analysis also had relatively small sample sizes, and showed considerable variability in both the molecular characteristics assessed and the techniques used to analyse them. Another important limitation is that we could not account for potential sampling bias in the original studies as some of the studies did not report on the proportion of total number of polyps sampled for molecular analysis. Further, the criteria used in the selection of polyps sampled for molecular analyses were not specified in any of the studies.

The number of studies which could be included in our meta‐analysis was considerably limited by a lack of conformity and consistency for reporting this rare syndrome. Despite finding 4561 potentially relevant studies, our meta‐analysis was limited to only 14 studies, mostly as a result of reporting discrepancies. These include: participant inclusion criteria not adhering to the WHO definition for serrated polyposis, lack of quantitative description of the total number of serrated polyps identified and the number sampled, and failure to distinguish results pertaining to subjects with serrated polyposis from those without. Furthermore, research in serrated polyposis thus far has focused predominantly on serrated polyps and the 'serrated' pathway to CRC. As serrated polyposis is a relatively rare condition, future molecular characterisation of this syndrome will always be hindered by small sample sizes and study population heterogeneity. Pooling of studies from different centres will be crucial in improving the understanding of the molecular pathways involved in the condition. Therefore, we propose a set of minimum standards for the reporting of studies in serrated polyposis (Table [3](#cjp244-tbl-0003){ref-type="table-wrap"}) to guide future research into the molecular underpinnings of this rare syndrome. In addition to satisfying the WHO criteria for serrated polyposis, future investigators should ensure that they provide basic demographic information about the patients enrolled into the study and, ideally, report the total numbers of serrated polyps, conventional adenomas and CRCs in study participants. In order to minimise sampling bias, it would also be important to report on the proportion of polyps that is sampled for molecular analyses and any specific criteria used in the selection of polyps. Many older studies have restricted their attention to one or two molecular hallmarks of the 'serrated' pathway, thereby limiting the interpretation of these findings in the context of the molecular heterogeneity of CRC. It is therefore suggested that a core panel of molecular markers, including MSI or mismatch repair deficiency, CIMP, mutations in *BRAF* and *KRAS* be incorporated into any novel molecular markers under investigation. Consideration should also be given as to whether germline sequencing was undertaken and if so by what method. The resultant standardisation of molecular research reporting will facilitate consistent and accurate data collection, comparison of pathological and molecular findings between different studies, and enable research into identifying the molecular mechanisms underlying this enigmatic condition.

###### 

New proposed minimum standards for reporting of molecular characteristics in serrated polyposis

  Required data
  ----------------------------------------------------------------------------------------
  Subjects must satisfy the WHO criteria for serrated polyposis
  Age and gender
  Serrated polyps: histological classification, total number and the number sampled
  Conventional adenomas (if present): total number and the number sampled
  CRC (if present): location and proximity to serrated polyp and/or conventional adenoma
  **Recommended data**
  Comment on whether germline sequencing has been undertaken and if so by what method
  Panel of core molecular markers
  1\. MSI
  2\. Mutations in *BRAF* and *KRAS*
  3\. Mismatch repair deficiency (MLH1, MSH2, MSH6, and PMS2)
  4\. CIMP
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###### 
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